SINTX Technologies Inc(SINT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 4:02 PM ET (Korea 11/4 06:02)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.47 | Insider Own | 19.8% | Shs Outstand | 6.6M | Perf Week | 0.58% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 40.98% | Insider Trans | - | Shs Float | 6.1M | Perf Month | -21.1% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.31 | Inst Own | 12.79% | Short Float | 2.25% | Perf Quarter | -1.15% |
| Income | -0.02B | P/S | 9.77 | EPS this Y | 70.29% | Inst Trans | 30.06% | Short Ratio | 1.2 | Perf Half Y | -28.93% |
| Sales | 0.00B | P/B | 2.35 | EPS next 5Y | 54.77% | ROA | -114.97% | Short Interest | 0.14M | Perf YTD | -55.44% |
| Book/sh | 0.73 | P/C | 3.62 | EPS past 3/5Y | 92.03% 80.47% | ROE | -255.86% | 52W High | -61.43% ($4.46) | Perf Year | -48.5% |
| Cash/sh | 0.48 | P/FCF | - | Sales past 3/5Y | -13.28% 11.38% | ROIC | -151.36% | 52W Low | 22.86% ($1.40) | Perf 3Y | -97.94% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 47.55% | Gross Margin | 28.87% | Volatility(W/M) | 4.64% 6.4% | Perf 5Y | -99.99% |
| Dividend TTM | - | EV/Sales | 9.44 | Sales Y/Y TTM | -28.53% | Oper. Margin | -884.81% | ATR (14) | 0.12 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 1.6 | EPS Q/Q | 18.09% | Profit Margin | -1423.01% | RSI (14) | 44.73 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.36 | Sales Q/Q | 199.34% | SMA20 | -4.87% ($1.81) | Beta | 0.56 | Target Price | $9.25 |
| Payout | - | Debt/Eq | 0.65 | Earnings | 2026/11/5 | SMA50 | -4.35% ($1.8) | Rel Volume | 0.25 | Prev Close | $1.71 |
| Employees | 32 | LT Debt/Eq | 0.54 | EPS/Sales Surpr. | -2.74% -1.74% | SMA200 | -22.19% ($2.21) | Avg Volume(3M) | 0.11M | Price | $1.72 |
| IPO | 2014/2/13 | Option/Short | No/Yes | Trades | 226 | Volume | 28,094 | Change | 0.58% |
🦴 A medical device innovation company that develops and sells spinal and orthopedic implants based on silicon nitride material. It is a mid-sized medical device company leading the clinical application of high-performance biomedical materials.
Over the past 1 year, on the lower side
61% below its 1-year high.
Traded less than usual. That is 25% of its average volume.
Next earnings report: November 5
1 days to go.
SINT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +70.3% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $977. Peers typically go for $145.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 12.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
DFAC U.S. Core Equity 2 Portfolio-ETF Class Shares <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #115 of 140 in the industry
Based on market cap of $13M.
PAVM#113 PAVmed Inc $15M PER - 
CTSO#114 Cytosorbents Corp $14M PER - SINT#115 SINTX Technologies Inc $13M PER - 
PLSM#116 Pulsenmore Ltd $12M PER - 
IRIX#117 IRIDEX Corp $12M PER - 
FAQ
What kind of company is SINT?
SINT belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of SINT?
The market cap of SINT is approximately $13M, ranking 5,347 within its sector.
What is the 52-week high and low for SINT?
SINT has recorded a 52-week high of $4.46 and a low of $1.40.
